Abstract:Abstract Pharmacological inhibition of proteasomal cysteine deubiquitinase (DUB) activity (i.e., USP14 and UCHL5 DUBs) has been shown to be particularly cytotoxic to cancer cells and to result in inhibition of tumor growth in several in vivo models. Most proteasome DUB inhibitors contain α, β-unsaturated ketones with the potential to covalently bind DUB active site cysteines. We here performed a screen of 5000 compounds containing α, β-unsaturated ketones in order to identify novel proteasome DUB inhibitors and to examine the question of the specificity of such compounds. Surprisingly, only ~3% of 5000 compounds containing α, β-unsaturated ketones showed anti proliferative activity at 5 uM. Almost one third of these cytotoxic compounds were found to block proteasome processing. Treatment of cells with the hit compounds induced the accumulation of proteasome bound high molecular weight polyubiquitin conjugates, induction of the chaperone HSP70B' and the oxidative stress marker heme oxygenase-1 (HO-1) and to induce an apoptotic response. A subset of 10 compounds were studied in detail and found to inhibit proteasome DUB activity in vitro. Importantly, hit compounds did not show inhibitory activity on a panel of recombinant non-proteasome DUBs. Inhibition of proteasome processing by hit compounds was not due to inhibition of 20S proteasome enzymatic activity. Exposure of multiple myeloma cells to the hit compounds resulted in thermostabilization of USP14 at the relevant concentrations using CETSA. These results suggest that α, β-carbonyls-containing compounds are promising candidates for development of drugs targeting proteasome DUBs and that drugs showing unexpected selectivity can be identified. Citation Format: Karthik Selvaraju, Arjan Mofers, Paola Pellegrini, Ellin-Kristina Hillert, Padraig D'Arcy, Stig Linder. Screening and characterization of drugs that inhibit the ubiquitin-proteasome system [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2795.

Covalent Fragment Screening and Optimization Identifies the Chloroacetohydrazide Scaffold as Inhibitors for Ubiquitin C-terminal Hydrolase L1

Optimization and Anti-Cancer Properties of Fluoromethylketones as Covalent Inhibitors for Ubiquitin C-Terminal Hydrolase L1

Fragment-Based Covalent Ligand Screening Enables Rapid Discovery of Inhibitors for the RBR E3 Ubiquitin Ligase HOIP

A high-throughput screen of pharmacologically active compounds for inhibitors of UHRF1 reveals epigenetic activity of anthracycline derivative chemotherapeutic drugs.

Identification of small‐molecule binding sites of a ubiquitin‐conjugating enzyme‐UBE2T through fragment‐based screening

A Potent and Selective Inhibitor for the UBLCP1 Proteasome Phosphatase.

Cellular Validation of a Chemically Improved Inhibitor Identifies Monoubiquitination on OTUB2

A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

Altered protein dynamics and a more reactive catalytic cysteine in a neurodegeneration-associated UCHL1 mutant

Structural Dynamics of the Ubiquitin Specific Protease USP30 in Complex with a Cyanopyrrolidine-Containing Covalent Inhibitor

Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10.

Abstract 2795: Screening and characterization of drugs that inhibit the ubiquitin-proteasome system

Ubiquitin C-terminal Hydrolases L1:Physiological and Pathological Significance

Design of linked-domain protein inhibitors of UBE2D as tools to study cellular ubiquitination

Chimeric deubiquitinase engineering reveals structural basis for specific inhibition of USP30 and a framework for DUB ligandability

A Cell-Based High-Throughput Screening Method Based on a Ubiquitin-Reference Technique for Identifying Modulators of E3 Ligases.

Identification and characterization of UBA5 inhibitors

Cheminformatics-aided discovery of potential allosteric site modulators of ubiquitin-specific protease 7

E2 Enzyme Inhibition by Stabilization of a Low-Affinity Interface with Ubiquitin.

Validation of Catalytic Site Residues of Ubiquitin Specific Protease 2 (USP2) by Molecular Dynamic Simulation and Novel Kinetics Assay for Rational Drug Design